Adherence and persistence in patients with severe osteoporosis treated with teriparatide

Current Medical Research and Opinion

Volumn 26, Issue 3, 2010, Pages 675-681

  Ziller, V ^a   Zimmermann, S P ^a   Kalder, M ^a   Ziller, M ^a   Seker Pektas, B ^a   Hellmeyer, L ^a   Hadji, P ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34];

AGED; ARTICLE; BACKACHE; DISEASE SEVERITY; DRUG COST; DRUG TOLERABILITY; FEMALE; GERMANY; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PAIN ASSESSMENT; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SELF REPORT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

AGE FACTORS; AGED; BONE DENSITY CONSERVATION AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TERIPARATIDE; TIME FACTORS;

EID: 76949085469     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903538409     Document Type: Article

References (28)

1. Borgstrom F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006;175:637-650
2. Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004;152:108-112
3. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;1512:1003-1008
4. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and non-vertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 818:1013-1022
5. Silverman SL, Gold DT, Cramer JA. Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J 2007;10012:1214-1218
6. Curtis JR, Westfall AO, Cheng H, et al. Benefit of adherence with bispho-sphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008;239:1435-1441
7. Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 1222(Suppl.):S3-13
8. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997;13811:4607-4612
9. Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine 2008;753:303-310
10. Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;188:1023-1031
11. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 483:271-287
12. Bartl R, Gotte S, Hadji P, et al. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]. Dtsch Med Wochenschr 2006;13122:1257-1262
13. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;176:914-921
14. Haynes RB, Montague P, Oliver T, et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2000; 2:CD000011
15. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;34419:1434-1441
16. Gallagher JC, Genant HK, Crans GG, et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005;903:1583-1587
17. Hess. Arzneimittelrichtlinie AMR/Therapiehinweis Teriparatid. Deutsches Ä rzteblatt 2007;104:1043-1048
18. Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009;203:431-436
19. WHO. Adherence Project. WHO Publications, 2003
20. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;111:44-47
21. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;241: 67-74
22. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;219:1453-1460
23. Ziller V, Ossendorf A, Funk E, et al. Compliance in der Therapie der Osteoporose mit wöchentlicher Bisphosphonatgabe-Analyse einer Zufallsstichprobe aus der klinischen Praxis. Osteologie 2007;16(Suppl. 1): 5-10
24. Ziller V, Wetzel K, Hadji P. Adherence and Persistence in Patients with Postmenopausal Osteoporosis Treated with Raloxifene. J Bone Miner Res Annual Meeting Abstract, 2009
25. Arden NK, Earl S, Fisher DJ, et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 2006;1711:1626-1629
26. Briot K, Ravaud P, Argent-Molina P, et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int 2008;20:625-630
27. Lincoln TM, Wilhelm K, Nestoriuc Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res 2007;961-3:232-245
28. Ziller V, Zimmermann S-P, Hadji P. Adherence in Patients with Severe Osteoporosis Treated with Teriparatide. J Bone Miner Res, Annual meeting abstract 2008;Poster M384